• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Extracellular RNAs as potential biomarkers for cancer

    2020-07-20 03:48:08ChristineHappelAniruddhaGangulyDaniloTagle

    Christine Happel, Aniruddha Ganguly, Danilo A.Tagle

    1National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD 20892, USA.

    2Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute at the National Institutes of Health, Bethesda, MD 20892, USA.

    Abstract The discovery that all cells secrete extracellular vesicles (EVs) to shuttle proteins and nucleic acids to recipient cells suggested they play an important role in intercellular communication.EVs are widely distributed in many body fluids, including blood, cerebrospinal fluid, urine and saliva.Exosomes are nano-sized EVs of endosomal origin that regulate many pathophysiological processes including immune responses, inflammation, tumour growth, and infection.Healthy individuals release exosomes with a cargo of different RNA, DNA, and protein contents into the circulation, which can be measured non-invasively as biomarkers of healthy and diseased states.Cancer-derived exosomes carry a unique set of DNA, RNA, protein and lipid reflecting the stage of tumour progression, and may serve as diagnostic and prognostic biomarkers for various cancers.However, many gaps in knowledge and technical challenges in EVs and extracellular RNA (exRNA) biology, such as mechanisms of EV biogenesis and uptake, exRNA cargo selection, and exRNA detection remain.The NIH Common Fund-supported exRNA Communication Consortium was launched in 2013 to address major scientific challenges in this field.This review focuses on scientific highlights in biomarker discovery of exosome-based exRNA in cancer and its possible clinical application as cancer biomarkers.

    Keywords: Extracellular vesicles, exosomes, extracellular RNA, cancer, biomarker, liquid biopsy

    INTRODUCTION

    Once thought to exist only within cells, RNA is now known to play a role in a variety of complex cellular functions.Recent research has shown that RNA can be exported from cells and plays a role in the molecular mechanisms of cell-to-cell communication[1,2].This paradigm-shifting observation launched the field of extracellular RNA (exRNA) biology and represents a fundamental change in our understanding of RNA in cell biology.

    Extracellular RNA acts as a signalling molecule, traveling though body fluids carrying information from cell to cell.Types of exRNA include both longer messenger RNA (mRNA) and long non-coding RNA (lncRNA),as well as various types of small non-coding RNAs (ncRNAs).Non-coding RNAs can generally be broken down into two groups, regulatory ncRNAs and housekeeping ncRNAs, as outlined in Table 1.Regulatory ncRNAs include lncRNA, microRNA (miRNA), piwi-interacting RNA (piRNA), small interfering RNA(siRNA), tRNA-derived fragments and Y RNA.Regulatory small ncRNAs have emerged as vital players in various biological processes.They are known primarily for their role as regulators of gene expression at the post-transcriptional level; however, they have a wide range of functions.Further information on individual ncRNAs can be found in the review articles cited in Table 1.Housekeeping ncRNAs include ribosomal RNA (rRNA), transfer RNA (tRNA), small nuclear RNA (snRNA), and small nucleolar RNA (snoRNA).Housekeeping ncRNAs are highly abundant and are essential for cellular activities such as the translation of RNA into proteins, and transcriptional splicing.The term exRNA includes many types of RNA.Small non-coding exRNAs are often the focus of studies due to their abundance, ease of detection, and regulatory function.MiRNA are of particular interest due to their role in post-transcriptional regulation of gene expression.Changes in miRNA expression are associated with various pathological conditions and dysregulation of miRNA expression is a hallmark of human cancer[3].

    Extracellular RNA is secreted by all cell types and can be found in a variety of biofluids including plasma,serum, breast milk, saliva, cerebrospinal fluid (CSF), bile, semen, and urine[4-7].While many ncRNAs are found in human biofluids, miRNA, piRNA, snoRNA, tRNA-derived RNA fragments (tRF), and Y RNA represent the most prominent types of exRNA found within various human biofluids (Figure 1 and Table 1, asterisks)[4,8].Carriers of exRNA include extracellular vesicles (EVs), ribonucleoprotein complexes(RNPs), and lipoprotein complexes (LPPs).ExRNAs are either encased within extracellular vesicles, or, are tightly associated with proteins to avoid degradation by RNAses.ExRNAs, in extracellular vesicles and/or associated with protein complexes, can then be transferred from donor cells to recipient cells, where they can elicit functional responses and regulate a number of biological processes[9,10].

    Table 1.General classification of non-coding RNAs

    EVs, released by virtually all cell types, are small membrane-enclosed carriers of bioactive proteins, lipids,and nucleic acids (including exRNAs)[11].Cells release a variety of EVs to transfer biological cargo to local and distant recipient cells within the body to facilitate intercellular communication.The term extracellular vesicles is broadly used for particles released from the cell that are delineated by a lipid bilayer, however,there are multiple EVs subtypes which can be differentiated based on their size, biogenesis, release pathways, cargo, and function[12].The main EV subpopulations include microvesicles (MVs), and exosomes.MVs are approximately 100-1000 nm in size and are derived from outward blebbing of the plasma membrane.Exosomes are approximately 30-100 nm vesicles of endosomal origin[13].The biogenesis of exosomes begins with the formation of early endosomes by inward budding of the cell membrane, followed by second inward budding of the endosomal membrane creating intraluminal vesicles (ILVs) and the larger multivesicular bodies (MVBs).Fusion of the MVBs with the plasma membrane release ILVs as exosomes into the extracellular milieu.Cytosolic constituents such as proteins and nucleic acids can be sorted into both types of EVs as part of their respective biogenesis pathways [Figure 2].

    Figure 1.A schematic diagram showing exRNA types predominantly found in a representative set of human biofluids.miRNA: microRNA;piRNA: piwi-interacting RNA; tRF: tRNA-derived RNA fragments

    Figure 2.A schematic diagram showing the biogenesis pathway of microvesicles and exosomes.Microvesicles are formed by direct budding from the plasma membrane and are capable of encapsulating multiple forms of molecular cargo including proteins and nucleic acids.The biogenesis of exosomes begins with internalization of the cell membrane leading to the formation of early endosomes.Intraluminal vesicles (ILVs) are formed by the inward invagination of endosomal membranes, resulting in the formation of multivesicular bodies (MVBs).During this process, cytosolic constituents, including nucleic acids and proteins, can be sorted into ILVs.Upon fusion of MVBs with the plasma membrane, ILVs are released as exosomes into the extracellular milieu.Exosomes can include many different types of exRNA as listed in Table 1.ER: endoplasmic reticulum; MLV: multivesicular body; ILV: intraluminal vesicle; miRNA: microRNA;piRNA: piwi-interacting RNA; tRF: tRNA-derived RNA fragments; snoRNA: small nucleolar RNA; lncRNA: long non-coding RNA

    Non-vesicle associated carriers include ribonucleoprotein (RNP) and lipoprotein (LPP) complexes.These non-membrane bound exRNA carriers have been shown to be present in human plasma and serum[14,15].The LPP family of complexes are classically regarded as carriers of lipids and can be further broken down into high-density lipoproteins (HDLs), low-density lipoproteins (LDLs), very LDLs (VLDLs), and chylomicrons based on their mass density.Recent studies have revealed that lipoproteins, such as HDLs and LDLs, can transport miRNAs and deliver them to recipient cells where they carry out their functional roles[16,17].One of the main interests in exRNA research is focused on their ability to mediate intercellular communication and act as signalling molecules in normal cell homeostasis, or as a consequence of pathological development.The exRNAs demonstrated potential as cancer biomarkers due to their function.There are published reports to support the use of exRNA for both cancer diagnosis and prognosis[18].

    This article focuses on exosome-derived exRNAs obtained non-invasively from liquid biopsy as potential biomarkers for the early detection and monitoring of cancers.Developing biomarkers based on exRNA isrelevant and important in the context of precision cancer therapy, since this approach will result in noninvasive procedures using body fluids as test samples, and essentially eliminate unnecessary repeat biopsies for diagnosis and monitoring effectiveness of a therapy[19].ExRNAs are now being evaluated as biomarkers in a variety of cancers and this review provides an understanding of the present status of exosome/exRNA-based cancer biomarker research, acknowledges challenges, and addresses the need to identify, develop,and validate clinically relevant exosomal exRNAs as cancer biomarkers.

    LIQUID BIOPSY

    Liquid biopsy is a term generally used to describe the collection of a body fluid to test for diagnostic information that will guide patient management.Various biological fluids can be used for liquid biopsies,but blood is one of the most accessible fluids along with urine and saliva[20].The ultimate goal of liquid biopsies in cancer patients is to be informative about the underlying tumour biology and establish biomarker clinical utility with clear prognostic value.Non-invasive measurement of cancer biomarkers using liquid biopsy allows for patient stratification, screening, monitoring treatment response, and detecting minimal residual disease following therapy/surgery and recurrence.The emergence of sensitive nucleic acid and protein biomarkers detection technologies have enabled the development of liquid biopsies with clinical applications in oncology.Currently, tumour biopsy is the preferred diagnostic tool available to clinicians to detect and monitor treatment for cancer.Since many tissues are difficult or impossible to biopsy or resect, and biopsies cannot provide information on treatment efficacy in real-time, RNA-based biomarkers are being developed to address these issues.A liquid biopsy platform that enables non-invasive real-time detection of cancer biomarkers may significantly reduce the need for tissue biopsy.Advancements in liquid biopsies are a key objective of precision oncology, with the goal of improving the diagnosis and treatment of cancer[21].

    Tumour derived liquid biopsy analytes in the blood include circulating tumour cells (CTC), circulating tumour DNA (ctDNA), exRNA, exosomes, and EVs[21].CTCs and ctDNA are the two analytes that have more reported utility than others as biomarkers in precision oncology.CTCs are tumour cells that have presumably been shed from the primary tumour and/or metastatic lesions into the bloodstream.CtDNA can be detected in the blood as part of the total cell-free DNA (cfDNA) pool, but is specifically derived from cancerous cells[22].Clinical applications for CTCs and cfDNA include prediction of cancer prognosis,selection and monitoring of therapeutic regimens, and drug target applications[21].

    Current challenges in cancer diagnostics using liquid biopsy

    While liquid biopsies are increasingly being used for molecular diagnostics in oncology, challenges remain.One limitation in using CTCs for clinical applications is the scarcity of CTCs in the blood.The abundance of CTCs in the blood is low (approximately 1 cell per 1 × 109blood cells in patients with metastatic cancer),and only a limited number of CTCs can be isolated from a single blood sample[23-25].Similarly, ctDNA concentration can vary from 0.01% to 90% of total cfDNA and, in general, the amount of ctDNA increases with tumour burden[26,27].These extreme low concentrations can make detection and analysis challenging.While CTCs can be analysed at the DNA, RNA, and protein levels, and provide information on functional cellular characteristics, analyses of CTCs provide limited information on tumour heterogeneity[28,29].

    CtDNA provides a more comprehensive view of the tumour genome as it reflects DNA released from multiple tumour regions or different tumour foci to capture tumour heterogeneity[30-32].However, due to the high fragmentation rate and low abundance of ctDNA, and high background levels of wild-type DNA in blood, the analysis is particularly challenging.Whole genome sequencing of cfDNA suggests both cfDNA and ctDNA are likely derived from apoptotic cells[33].While CTCs are shed from a tumour once it reaches a certain stage in development and ctDNA is released from dying cells, exRNA secretion (biogenesis) is a normal cellular process.This makes exRNA and EVs better candidates to provide insight into early stage cancers where cell death is not yet occurring.

    LIQUID BIOPSY AND EXRNA

    ExRNAs and EVs are among the liquid biopsy analytes that have demonstrated potential as cancer biomarkers due to their function, availability in most body fluids, and ability to be collected in a noninvasive manner, allowing frequent and longitudinal sampling.In cancer research, there is substantial evidence to support the use of exRNA for both diagnostic and prognostic purposes[18].Differential expression of cellular and extracellular miRNAs has been associated with a wide range of human diseases[34].While exRNA can include many diverse types of RNA species (as discussed above), most studies investigating the use of exRNAs as biomarkers have focused on miRNAs since its expression patterns are unique to individual tissues and differ between cancer and apparently uninvolved tissues[35].Y RNA is abundantly expressed in multiple body fluids and increased levels of Y RNA have been observed in the circulation of cancer patients[5,36].These observations have triggered interest in the potential use of Y RNA as a biomarker for cancer and other diseases.However, many other types for exRNAs are being explored as potential biomarkers, including mRNA mutations and other non-coding RNAs[18].

    There are opportunities for exRNA to be developed into reliable biomarker tests for cancer detection using liquid biopsy samples, since exRNA is remarkably stable and resists degradation mediated by ribonucleases[15,37].The discovery of stable RNA or exRNA outside of cells is continuously changing the fundamental understanding of intercellular signalling and of the role RNA may play in cell-to-cell communication and other complex biological processes.Because of their relative stability within vesicles or in association with RNPs and LPPs, and, marked differences between exRNAs secreted by apparently normal and tumour cells, exRNA molecules have high potential for development as biomarkers of various cancers including lung[38], breast[39]and prostate cancers[40,41].

    ADVANTAGES OF EXRNA IN LIQUID BIOPSY

    The remarkable stability and relatively non-invasive access of different exRNA molecules makes them an interesting class of biomarkers.The stability of exRNAs have been testedex vivounder various conditions including freeze-thaw cycles, extreme pH values, and storage at room temperature (RT)[42].Examination of exRNA from CSF or blood in the diagnosis of glioma revealed that the EV number and morphology remained largely unchanged if CSF was stored at RT[43].The total RNA and representative miRNA levels were well-preserved under this condition for up to a week, and a single cycle of freezing and thawing did not significantly alter EV number, morphology, RNA content, or miRNA levels, confirming its stability at RT.These findings demonstrated stability and the incredible ease and speed of obtaining specimens for testing compared to conventional biopsy.Measuring circulating RNA as liquid biopsy is a reliable alternative to conventional biopsies, offering a potentially cheaper, reliable, and non-invasive way of monitoring cancer development, progression, and remission.

    Most of the tests for disease diagnosis and monitoring used in clinics are based on specific protein concentration changes in body fluids.In comparison to protein-based biomarkers, exRNA has several advantages including easier developed assays with specificity, and an amplifiable detection signal.Measuring low abundance RNA in biofluids also circumvents the inherent obstacle of high protein concentration and complexity in human body fluids in liquid biopsy.

    In various diseases, normal EV cargo contents change as diseases initiate, and progress, altering the types of proteins and RNAs that are packaged.These changes are rapid and quantitative[44].Therefore, the exRNA profile of an individual may provide a snapshot of their health.Real-time changes in expression of exRNA offer prognostic values in predicting disease outcomes, monitoring treatment response and assessing treatment risk[45].

    EXRNA AS CLINACAL BIOMARKERS

    In order to develop exRNAs as clinical biomarkers, the development process has to go through rigorous steps to define the intended target, examine clinical utility (must inform and guide patient treatment,management, and outcomes) and, validate the test both analytically (ensures specificity, accuracy, precision,and other characteristics of a biomarker test or device) and clinically (ensures that the test or device performs as intended) before clinical application.Since the U.S.Food and Drug Administration (FDA) is the regulatory body to qualify biomarkers for intended clinical studies, it is therefore relevant to understand the FDA definition of a biomarker and review various resources available for investigators.

    FDA’s definition of a biomarker

    The FDA defines a biomarker as a defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions[46,47].Qualified biomarkers have the potential to provide valuable information that may reduce uncertainty in regulatory decisions during drug development.When a biomarker is qualified,it means that it has undergone a formal regulatory process to ensure that it is reliable and reproducible for a specific interpretation and application in medical product development and regulatory review, within the stated context of use.

    FDA BEST biomarker categories resource

    It is essential to have effective, unambiguous communication for efficient translation of promising scientific discoveries into approved medical products.Unclear definitions and inconsistent use of key terms can hinder the evaluation and interpretation of scientific evidence and may pose significant obstacles to medical product development programs.

    The FDA-NIH Joint Leadership Council identified harmonization of terms used in translational science and medical product development as a priority need, with a focus on terms related to study endpoints and biomarkers.Working together with the goals of improving communication, aligning expectations, and improving scientific understanding, the FDA and NIH developed the BEST (Biomarkers, EndpointS, and other Tools) resource for biomarker researchers[46].BEST defines seven biomarker categories: susceptibility/risk, diagnostic, monitoring, prognostic, predictive, pharmacodynamic/response, and safety.The BEST glossary aims to capture distinctions between biomarkers and clinical assessments and describes their distinct roles in biomedical research, clinical practice, and medical product development.

    FDA center for drug evaluation and research biomarker qualification program

    The mission of this program is to work with external stakeholders to develop biomarkers as drug development tools.Qualified biomarkers have the potential to advance public health by encouraging efficiencies and innovation in drug development.The goals of the biomarker qualification program (BQP)are to (1) support outreach to stakeholders for the identification and development of new biomarkers; (2)provide a framework for the review of biomarkers for use in regulatory decision-making; and (3) qualify biomarkers for specific contexts of use that address specified drug development needs.

    Biomarker qualification is a process involving three stages that provide increasing levels of detail for the development of a biomarker for its proposed context of use.The processes to complete submissions to the center for drug evaluation and research (CDER) BQP are (1) a letter of intent (LOI); (2) qualification plan;and (3) full qualification package.More information about the FDA CDER BQP can be found on their website[47].A Pre-LOI meeting can be helpful for requesters to receive guidance from the FDA regarding their biomarker programs before submission to the program[48].Once a biomarker is qualified it can then be used in multiple drug development programs for the context of use without FDA re-review.

    ExRNA as cancer biomarker

    Medical oncologists have been using cancer biomarker tests to guide molecularly targeted therapies to achieve better therapeutic outcomes.In this regard, developing biomarkers and biomarker tests based on exRNA is relevant and important in the context of precision cancer therapy.Investigators have been assessing the current state-of-the-art methods for body fluid sample collection, exRNA isolation, and analysis, with exRNA biomarker discovery as the goal.This data has been unified in a report on the current state of knowledge of exRNA isolation and analysis techniques[49].To avoid loss of potential biomarkers,investigators have been using comprehensive methods, such as qRT-PCR and cutting-edge platforms for RNA sequencing, rather than selection methods for specific RNA species.

    ExRNAs have already begun to demonstrate their utility as clinical biomarkers.A study by McKiernanet al.[50]reported the development of a urine exosome-based non-invasive gene expression assay that discriminates high-grade from low-grade prostate cancer and benign disease.In another study Liet al.[51]identified and validated a panel of salivary exRNA biomarkers for potential use in screening and risk assessment for gastric cancer.Using salivary gland secretions, investigators have identified 30 mRNA and 15 miRNA candidates whose expression patterns were associated with the presence of gastric cancer[51].These exRNA biomarkers were identified and validated with credible clinical performance for non-invasive detection of gastric cancer.Another recent study reported analysis of ctDNA and exRNA for monitoring tumour burden and therapeutic response in patients with multiple myeloma[52].This exploratory analysis has provided evidence of ctDNA for predicting disease outcome and the utility of exRNA as a biomarker of therapeutic response in multiple myeloma.It has been reported that an exosome-based detection of EGFR T790M in plasma from non-small cell lung cancer patients (NSCLC) may benefit from ALK (anaplastic lymphoma kinase) inhibitor therapy whose tissue samples are not available or who are unable or unwilling to undergo repeat biopsy[53].To address this need, Exosome Diagnostics developed an assay (ExoDxLung-ALK) in a CLIA certified laboratory to isolate and analyse exosomal RNA from blood samples enabling sensitive,accurate and real-time detection of EML4-ALK mutations in patients with NSCLC.

    Exosome Diagnostics has also developed a qPCR-based test (ExoDxEGFR) that interrogates mutations within theEGFRgene in NSCLC.The assay uses plasma derived exosomal RNA/DNA and cfDNA to detectEGFRmutations to inform clinical management[53,54].Castellanos-Rizaldos and colleagues compared this assay to the FDA approved companion diagnostic, cobas?EGFRMutation Test v2 (Roche), that detects defined mutations within theEGFRgene from plasma cfDNA liquid biopsy samples of NSCLC patients and found increased sensitivity and specificity using the ExoDxEGFRassay which they attributed to the exRNA-based assay design[53].

    EXRNAS AS BIOMARKERS OF CLINICAL SIGNIFICANCE IN CANCER

    To demonstrate the potential of exRNA and exosomes as clinical biomarkers, we mined data from current clinical trials exploring the utility of these liquid biopsy analytes in cancer.The ClinicalTrials.gov is a database for publicly and privately supported research studies conducted around the world.As of May 11th, 2020, there are 45 clinical trials on ClinicalTrials.gov that focus on the use of exRNA and exosomes as clinical biomarkers in cancer[55].The search results are summarized in Figure 3A-C.While a vast majority of the clinical trials are taking place in the U.S., there are many trials in other countries as well, including China, Italy, and Spain [Figure 3A].These clinical trials span a large variety of cancer types[Figure 3B].Lung and Prostate cancers are the most common disease models exploring the use of exRNA and exosomes as clinical biomarkers, as both cancer types are the focus of seven clinical studies.Overall,there is a large number of different cancer types represented in this data set.Fourteen out of the twenty different cancer types are the focus of one or two clinical studies, demonstrating the utility of exRNA and exosomes as clinical biomarkers.Blood is the primary biofluid utilized in these studies while urine is also a common source of biofluid used for liquid biopsies [Figure 3C].The combination of blood/serum/plasma is utilized for 34 out of the 45 clinical trials investigating the potential of exRNA and exosomes as clinical biomarkers, representing 17 different cancer types.Not surprisingly, urine is the biofluid of choice when investigating biomarkers for prostate cancer.However, clinical studies are also exploring the of use of urine as a biomarker for thyroid and kidney cancer.Saliva is an emerging biofluid that is inherently easy to collect, and, has been shown to reflect the spectrum of health and disease states found using serum[56,57].While there is only one clinical trial in this dataset using saliva for biomarker discovery, it is conceivable that emerging technological advancements will move saliva into the forefront as an accurate and reliable biofluid for molecular diagnostics.

    Figure 3.Current clinical studies evaluating the use of exRNA and exosomes as cancer biomarkers.An advanced search for query terms(“extracellular RNA” OR exosome OR exRNA OR oncosome) AND biomarker focused on cancer as a disease model, was performed on ClinicalTrials.gov on 11 May 2020.The search was restricted to recruitment statuses on recruiting, not yet recruiting, active, not recruiting,completed, enrolling by invitation, and studies of unknown status.The search returned 45 studies which are summarized in Figures 3AC.A: A world map shows the locations (in red) of all clinical studies evaluating the use of exRNA and exosomes as cancer biomarkers.The numbers indicate the clinical studies in each location; B: clinical trials were grouped by general cancer type and the number of studies focused on each cancer type are shown.Projects that did not specify cancer type were grouped together as non-specific cancer; C: the clinical trial data was parsed for the types of biofluids used in each study.Some studies examined multiple types of biofluids while other did not include biofluid sampling.The table represents biofluids examined in all 45 clinical studies

    Most studies investigating the use of exRNAs as biomarkers have focused on miRNAs, and indeed 12 of the 45 clinical trials in this dataset specifically examine the use of miRNAs as cancer biomarkers.However,two studies investigate mRNA as exosomal cargo and a molecular biomarker in cancer.Further, there is a clinical study looking at circular RNA (cRNA) in pancreatic cancer, and a study exploring exosome derived lncRNA in ovarian cancer.Notably, most of the clinical studies did not indicate a specific exRNA target.Overall, this data demonstrates widespread utility of exRNA and exosomes as clinical biomarkers across a spectrum of biofluids and cancer types.

    NIH-supported research focused on exRNA and exosomes as biomarkers in cancer

    The NIH supports many pre-clinical research projects focused on the use of exRNA and exosomes as biomarkers in cancer.To understand the breadth and type of research funded by NIH, we explored the Research Portfolio Online Reporting Tools Expenditures and Results Tool (RePORTER) using the website:https://projectreporter.nih.gov/reporter.cfm.An NIH RePORTER search for exRNA and exosomes as biomarkers in cancer found 138 projects that have been funded by NIH between 2010-2020, which is summarized in Figure 4A and B.NIH funded projects were grouped by funding type and the number of awards for each funding type can be found in Figure 4A.A large majority of these studies (87 out of 138) were research projects.However, the number of research training and career development awards indicate a growing number of trainees entering the field.The NIH Common Fund’s Extracellular RNA Communication Program (ERCP) funded eight projects focused on exRNA and exosomes as biomarkers in cancer.NIH Small Business Innovation Research (SBIR) awards make up 10 of the 138 projects.These SBIR awards included funding to Tymora Analytical Operations, Cognext Diagnostics, Abtelum Biomedical, Nanomaterial Innovation, Biofluidica, Nanoview Diagnostics, Accure Health, Ascent Bio-Nano Technologies and Microsensor Labs.

    Figure 4.NIH supported research focused on exRNA and exosomes as cancer biomarkers.An advanced text search for (“extracellular RNA” OR exosome OR exRNA OR oncosome) AND cancer AND biomarker was performed on NIH RePORTER (https://projectreporter.nih.gov/reporter.cfm) on 9 May 2020.The text search was limited to project abstracts, project title, and project terms, and was focused on new awards only (excluding subprojects), funded by any NIH Institute or Center from 2010-2020.The search returned 138 projects,which are summarized in Figures 4A and B.A: NIH funded projects were grouped by general funding types; B: NIH funded projects were grouped by general cancer type and the number of projects focused on each cancer type are shown.Projects that did not specify cancer type were grouped together as non-specific cancer

    A large majority (85 out of 138) of the NIH funded projects that focused on exRNA and exosomes as biomarkers in cancer were not directed toward any specific cancer type [Figure 4B].Furthermore, the 53 remaining projects were spread across 15 different types of cancer.

    Pancreatic cancer was the focus of 11 studies over the past 10 years and accounted for 8% of the total number of awards.Brain, liver, and prostate cancer were each investigated in 6 studies, and the remaining cancer types were each addressed 5 or less times.This data, along with the clinical trial data, suggest that exRNA and exosomes have great potential as biomarkers in a variety of cancer types and across many types of biofluids.The broad applicability, universal presence in human biofluids, general stability, and accessibility of exRNAs demonstrate their potential in disease detection, monitoring, and prognosis.

    FDA-approved exosome-based clinical diagnostics

    Exosome Diagnostics (a Bio-Techne brand) recognized an opportunity to utilize exRNA as a predictive marker for prostate cancer and developed a urine exosome gene expression assay that can identify highergrade prostate cancer among patients with elevated prostate-specific antigen (PSA) levels.This simple, noninvasive, urine-based test provides an EXO106 score derived from exosome ERG and PCA RNA levels normalized to SPEDEF mRNA copy number[50,58].The U.S.FDA granted Bio-Techne Breakthrough Device Designation to this test [ExoDx Prostate IntelliScore (EPI)], making it the first exosome-based liquid biopsy test to receive this designation, and Medicare coverage in 2019.Further, a recent publication demonstrated that the EPI test influenced the overall decision to defer or proceed with a biopsy and improved patient stratification in a prospective, randomized, blinded, two-armed clinical utility study[59].

    CHALLENGES IN EXRNA RESEARCH

    Even though the field of exRNA is very promising, there are challenges to this emerging area.A key barrier toward a comprehensive understanding of exRNA biology and function has been the heterogeneity of exRNA carriers, improved EV separation technologies, and EV targeting and cargo release.

    EV biogenesis and cargo loading

    ExRNA carriers include different particle subtypes such as EVs, RNPs, and LPPs, however, EVs have gained the most interest amongst these carriers.EVs are highly heterogeneous and can be further divided into different subpopulations that differ in size, density, morphology, and composition[60].EV subpopulations broadly include MVs and exosomes[60].An ongoing challenge in the field is to clearly discriminate between EVs, exosomes, and MVs.

    Different EV biogenesis pathways also result in exRNA content that is extremely diverse and heterogeneous;and the intracellular sorting mechanisms that direct exRNAs to specific export pathways are not well understood[61,62].Furthermore, the nature and abundance of EV cargoes are cell-type-specific and often influenced by the physiological or pathological state of the donor cell and the stimuli that modulate their production[63].EV heterogeneity and the complexity of its exRNA cargo are likely sources of variability in exRNA profiling.Understanding the molecular mechanisms modulating EV biogenesis, the heterogeneity in EV subtypes, and the physiological relevance of their exRNA cargo will be crucial in harnessing their utility as cancer biomarkers.

    Single vesicle EV isolation

    A major challenge to the field of exRNA includes improved EV separation technologies.The heterogeneity of EVs, their nanoscale size, and the ambiguity of EV subpopulations that often have overlapping characteristics, are significant barriers to understanding the contribution of each specific EV subtype in different pathological systems[60].Due to a substantial overlap in the physio-chemical properties of exRNA carriers, many commonly used isolation protocols do not unambiguously separate EVs subtypes, or even EVs from non-EV exRNA carriers (such as RNPs or LPPs)[64].The lack of biophysical and biochemical markers for many different exRNA carriers makes the analysis and interpretation of exRNA data uniquely challenging.To address the variability in exRNA profiling studies, Murillo and colleagues applied computational deconvolution to exRNA-seq and exRNA qPCR profiles found in the Extracellular RNAAtlas (https://exrna-atlas.org).Their analysis led to the identification of six exRNA cargo types found in multiple biofluids[65].While their findings suggest associations of cargo types with distinct carriers, it also demonstrated that the heterogeneity of exRNA carriers and cargo types exceeds the capabilities of current experimental methods to isolate and investigate specific carrier subpopulations and their cargo in a reproducible way[65].The generation and optimization of methods to isolate high purity exRNA subpopulations from biological samples, and, analyse the subsequent carrier exRNA contents, is a current goal in the field.

    EV targeting and cargo release

    To be functional in the context of cell-cell signalling, an EV must also be able to find its physiological target and release its cargo.But the question of how EVs target recipient cells can elicit a functional cellular response is still unknown.The specificity of targeting EVs to recipient cells is thought to occur through specific ligand-receptor interactions resulting in EV uptake.Mediators of these interactions include tetraspanins, integrins, lipids, lectins, heparan sulphate proteoglycans, and extracellular matrix components[60,66].Once EVs are bound to the recipient cells, many different types of endocytotic processes are known to mediate cellular uptake[13,60].Membrane fusion is an alternative entry method in cancer cells[67].However, different mechanisms of internalization have been described for different cell types, and the mode of EV entry into target cells is thought to play a role in the functional effects[66].It is possible that a population of EVs can simultaneously trigger a number of different methods of entry into a cell,with the primary entry points depending on the cell type and EV cargo[66].Understanding the mechanism of EV targeting and cargo release, and how this affects the functional fate of exRNA in recipient cells are outstanding questions in exRNA biology.

    ERCP

    The NIH Common Fund-supported Extracellular RNA Communication Program (ERCP) was launched in 2013 to accelerate progress in this new area of biomedical research.The overarching goal of the ERCP has been to accelerate progress in the field exRNA biology and establish exRNA, and their carriers, as mediators of intercellular communication.The first phase (stage 1) of the NIH Common Fund-supported Extracellular RNA Communication Consortium (ERCC1) addressed five major challenges in the exRNA field[68].The goals included: (1) to better understand the mechanisms of exRNA biogenesis, export and secretion from the cell of origin; (2) to develop reference profiles for exRNA species from healthy human biofluids; (3) to establish the utility of exRNA for biomarker development; (4) to establish the utility of exRNA for therapeutic development; and (5) to develop community-wide resources for exRNA standards,protocols, and data.The exRNA Portal (https://exrna.org/) is the central access point for ERCC resources including descriptions of all ERCC projects, exRNA data and data standards, protocols, and computational tools.

    While significant advances were made during ERCC Stage 1, the exRNA field still faces many challenges, in part due to both the inherent diversity of exRNA and the heterogeneity of exRNA carriers[61].In September 2019, the ExRNA Communication Program stage 2 (ERCC2) commenced to tackle the complexity of exRNA molecules and the diverse array of exRNA carriers.ERCC2 researchers will develop tools to efficiently and reproducibly isolate, identify, and analyse different carrier types and their exRNA cargos and allow analysis of one carrier and its cargo at a time.The three major initiatives addressed in Stage 2 of the ERCC include: (1) Improved Isolation and Analysis of exRNA-Carrier Subclasses; (2) Towards Single Extracellular Vesicle (EV) Sorting, Isolation, and Analysis of Cargo; and (3) to serve as a communitywide resource for exRNA standards, protocols, and data.The purpose of these initiatives is to further characterize the cell or tissue from which their respective exRNAs originate and shed light on the diversity of exRNAs carried by EVs.This will allow for a better understanding of the precise role of exRNAs as signalling molecules for both physiological and pathophysiological processes, ultimately accelerating the development of exRNAs for diagnostics.

    CHALLENGES OF EXRNA IN LIQUID BIOPSY

    Although exRNAs are more sensitive and specific biomarkers than proteins, and better reflect the cell dynamic than DNA does, there are limitations in the use of exRNA as biomarkers.EV heterogeneity and the complexity of its exRNA cargo, are sources of variability in exRNA profiling within and across studies, which has been a significant hinderance.To address the lack of consistency and reproducibility, Srinivasanet al.[69]demonstrated that exRNA sequencing reproducibility varies across isolation methods and that the performance of exRNA isolation methods can vary across biofluids and RNA species.To stimulate exRNA biomarker development, they developed miRDaR (https://exrna.shinyapps.io/mirdar/), an interactive webbased application to help investigators select the optimal exRNA isolation method for their studies based on the biofluid of interest.The development of standardized sample isolation and analysis procedures would allow a more meaningful comparison and integration of data from different studies, which may facilitate the development of exRNA based clinical applications.

    EVs are heterogeneous in nature and technical challenges remain in EV isolation.Current methods for isolating EVs from complex biofluids cannot clearly identify EV cellular origins within a pool of highly abundant vesicles.As such, there is no way to clearly differentiate cancer-derived EVs from healthy host cell-derived EVs in biofluids.However, ERCC2 efforts should be able to address this pressing challenge.A recent report described a process for EV enrichment by identifying cancer cell membrane proteins compared with healthy cell membrane proteins using TCGA Human Protein Atlas and GTEx,and presented isolation of tumour derived EVs from animal serum[70].This finding is encouraging to pursue exRNA biomarker research for detecting cancer at a very early stage.Better characterization of the differences between exRNA profiles of diseased and healthy individuals will allow the diagnostic and prognostic utility of exRNA-based profiling to increasingly becoming a reality[18,50,71].

    CURRENT STATUS OF EXRNA AS BIOMARKER

    It is conceivable that EVs, exosomes, and exRNA are important resources for developing cancer biomarkers.In this regard, a growing number of scientific reports suggest exRNA as a reliable non-invasive alternative to the invasive approaches for diagnosis, treatment and prognosis of cancer.Recently, a U.S.A.-based diagnostics company utilized exRNA as a predictive marker for prostate cancer, and developed a urine exosome gene expression assay to identify higher-grade prostate cancer among patients with elevated PSA levels[50,58].U.S.FDA granted Bio-Techne Breakthrough Device Designation to this test (ExoDx Prostate IntelliScore, EPI), which is the first exosome-based liquid biopsy test to receive this Designation.The National Comprehensive Cancer Center Network included EPI as a recommended test in their Clinical Practice Guidelines for Oncology for Prostate Cancer Early Detection (Version 1.2019).While this is a significant step forward in exosome/exRNA-based test development, advancement in this technology is required to address all types of cancers.

    The explosion of technological advancements including sophisticated bioinformatics and availability of better tools offer a wide spectrum of opportunities to explore exosomes/exRNA for developing reliable biomarker tests using liquid biopsy samples to accelerate real-time cancer diagnosis and molecularly guided therapy.

    However, there are challenges to isolate tumour-specific exRNA and use as biomarkers for clinical oncology due to inadequate separation technology and heterogeneity of exRNA carriers.Current methods for isolating EVs from complex biofluids does not clearly define the cell-of-origin or target cell of exRNA cargo and, therefore, are unable to determine with certainty the tissue of origin.This warrants improvement in EV separation technology, and better understanding of EV targeting and cargo release.

    The expectation is to develop liquid biopsy-based analytical assays using circulating exRNAs specific for the tumour type and to identify clinically relevant biomarkers useful as a diagnostic, prognostic or treatment response markers for cancer patients to fully appreciate its clinical potential as cancer biomarkers.

    FUTURE PERSPECTIVES

    The potential for the use of EVs, exosomes, and exRNAs in cancer biomarker development are starting to yield clinical utilities for diagnosing cancer, and as indicators of progression and/or treatment response.EVs derived from cancer cells appear to modulate the function and may induce epigenetic changes in distant recipient cells.Results from several studies as indicated in this review have already shown a prominent role of exRNAs associated with exosomes in instituting these changes.EVs can retain the molecular signature of the cell of origin, and its exRNA cargo has tremendous diagnostic potential.Since the identification of exRNAs in various human bio-fluids, an increasing number of studies have positioned exRNA as a new type of non-invasive biomarker with wide-ranging clinical potential.

    While significant advances have been made, the use of exosomes and exRNAs as cancer biomarkers faces remaining challenges that slows down its full potential from being realized.The NIH-led ERCC has supported research into the important roles of exRNAs in biological processes and its potential in molecular diagnosis, and to advance the technologies of exRNA identification and isolation from different types of bio-fluid.The ERCC has played critical roles in unmasking the mechanism of exRNA biogenesis, delivery and function; in defining a reference catalogue of exRNA in normal individual body fluids; in developing the clinical utility of exRNA as biomarkers of disease or as therapeutic molecules.The ERCC have also led the field in addressing major challenges in the field and providing valuable tools and technologies in this emerging field.

    Although a few exRNA biomarkers have been discovered individually for cancer diagnosis, a systematic identification of novel exRNA biomarkers will need to be further pursued through better isolation of homogeneous populations of exosomes and comprehensive analyses of their cargo.Currently, there are only limited mature exRNA biomarkers that could guide clinical decision making.Large cohorts with matched clinical information, including survival time, disease recurrence, response for drug usage or other information can be catalytic in the identification of novel exRNA biomarkers.Sufficient clinical cohorts are also required to validate the performance of biomarkers for early-diagnosis, prognosis and drug usage for precision oncology.

    In the future, it is also possible to target exRNAs as cancer therapeutic methods.The secretion and circulation of EVs that contain regulatory exRNAs can be blocked to prevent cancer from progressing and metastasis developing.In addition, exosomes could be used as a transmitter of specific regulatory elements into target cells, inhibiting the development of tumour.Some regulatory exRNAs that play roles in pivotal processes in tumour development could be repressed or sequestered to lower their abundance and inhibit their functions.In summary, exRNA is useful not only for liquid biopsies to diagnose various cancer types,but it also provides potential avenues for therapy.

    DECLARATIONS

    Authors’ contributions

    Conception and preparation of the manuscript: Happel C, Ganguly A, Tagle DA

    Availability of data and materials

    Not applicable.

    Financial support and sponsorship

    None.

    Conflicts of interest

    All authors declared that there are no conflicts of interest.

    Ethical approval and consent to participate

    Not applicable.

    Consent for publication

    Not applicable.

    Copyright

    ? The Author(s) 2020.

    99热这里只有精品一区| 国产精品一区www在线观看| 国产男人的电影天堂91| 国产乱人视频| 女人久久www免费人成看片| 高清在线视频一区二区三区| 亚洲欧美中文字幕日韩二区| 国产精品女同一区二区软件| 国产一区二区在线观看日韩| 1000部很黄的大片| 男女无遮挡免费网站观看| 干丝袜人妻中文字幕| 啦啦啦视频在线资源免费观看| 亚洲国产av新网站| 这个男人来自地球电影免费观看 | 欧美zozozo另类| 国产一区亚洲一区在线观看| 久久99蜜桃精品久久| 国产精品一区二区三区四区免费观看| 国产日韩欧美亚洲二区| 国产精品国产三级国产专区5o| 大码成人一级视频| 你懂的网址亚洲精品在线观看| 香蕉精品网在线| 少妇猛男粗大的猛烈进出视频| 久久99热这里只有精品18| 亚洲激情五月婷婷啪啪| 亚洲精品第二区| 亚洲欧洲日产国产| 黄片无遮挡物在线观看| 一个人看视频在线观看www免费| 如何舔出高潮| 国产成人免费无遮挡视频| 免费观看a级毛片全部| 夫妻性生交免费视频一级片| 99久久人妻综合| 国产成人a∨麻豆精品| 欧美bdsm另类| 黄色日韩在线| 国产高清三级在线| 黄色视频在线播放观看不卡| 一级片'在线观看视频| 亚洲真实伦在线观看| 三级经典国产精品| 日韩视频在线欧美| 亚洲精品成人av观看孕妇| 视频中文字幕在线观看| 国产黄色免费在线视频| 久久av网站| 在线观看人妻少妇| 亚洲精品成人av观看孕妇| 人人妻人人添人人爽欧美一区卜 | 美女国产视频在线观看| 两个人的视频大全免费| 国产精品99久久久久久久久| av在线app专区| 国产成人aa在线观看| 天天躁日日操中文字幕| 激情五月婷婷亚洲| 色婷婷av一区二区三区视频| 汤姆久久久久久久影院中文字幕| h日本视频在线播放| 国产又色又爽无遮挡免| 伊人久久精品亚洲午夜| 日韩欧美 国产精品| 三级经典国产精品| 国产成人精品一,二区| 亚洲国产精品成人久久小说| 久久韩国三级中文字幕| 我要看日韩黄色一级片| 免费久久久久久久精品成人欧美视频 | 黄片wwwwww| 国产精品一区二区性色av| 亚洲成色77777| 亚洲精华国产精华液的使用体验| av在线app专区| 久久精品国产亚洲av天美| 韩国高清视频一区二区三区| 黄色视频在线播放观看不卡| 免费观看的影片在线观看| 欧美成人a在线观看| 亚洲av电影在线观看一区二区三区| 最近最新中文字幕免费大全7| 久久精品人妻少妇| 亚洲第一区二区三区不卡| 尤物成人国产欧美一区二区三区| 免费观看的影片在线观看| av一本久久久久| 啦啦啦在线观看免费高清www| 少妇人妻久久综合中文| 一区在线观看完整版| 国产真实伦视频高清在线观看| 亚洲电影在线观看av| 国产精品一区二区三区四区免费观看| 国产精品99久久久久久久久| 亚洲人成网站在线观看播放| 中文字幕久久专区| 久久久久久人妻| 干丝袜人妻中文字幕| 少妇熟女欧美另类| 水蜜桃什么品种好| 国产老妇伦熟女老妇高清| 午夜福利视频精品| 久久97久久精品| 舔av片在线| 精品一区在线观看国产| 国产亚洲91精品色在线| 亚洲一级一片aⅴ在线观看| 亚洲一级一片aⅴ在线观看| 99久久中文字幕三级久久日本| 亚洲无线观看免费| 成人综合一区亚洲| 观看免费一级毛片| 涩涩av久久男人的天堂| 亚洲精品456在线播放app| 蜜桃亚洲精品一区二区三区| 国产中年淑女户外野战色| 亚洲人与动物交配视频| 水蜜桃什么品种好| 中文字幕亚洲精品专区| 久久久久久人妻| 老熟女久久久| 观看免费一级毛片| 国产高清三级在线| 成人综合一区亚洲| 97超碰精品成人国产| 欧美老熟妇乱子伦牲交| 色5月婷婷丁香| 伊人久久精品亚洲午夜| 人妻制服诱惑在线中文字幕| 精品少妇黑人巨大在线播放| 国产成人freesex在线| 亚洲欧美日韩东京热| 国产精品一区二区三区四区免费观看| 国产男女超爽视频在线观看| 久久久久久久久久久免费av| av福利片在线观看| 午夜福利在线观看免费完整高清在| 亚洲第一区二区三区不卡| 成人毛片60女人毛片免费| 男的添女的下面高潮视频| 日韩人妻高清精品专区| 一区二区三区精品91| 国产真实伦视频高清在线观看| 少妇丰满av| 国产成人91sexporn| 欧美精品国产亚洲| 成人影院久久| 久久久久久久精品精品| 欧美zozozo另类| 国产成人免费无遮挡视频| 亚洲av福利一区| 久久久欧美国产精品| 久热这里只有精品99| 国产亚洲5aaaaa淫片| 亚洲av日韩在线播放| 赤兔流量卡办理| 丝袜喷水一区| 97在线人人人人妻| 尤物成人国产欧美一区二区三区| 老熟女久久久| 新久久久久国产一级毛片| 极品少妇高潮喷水抽搐| 老师上课跳d突然被开到最大视频| 国产日韩欧美在线精品| 在线观看一区二区三区激情| 一个人免费看片子| 国产乱人偷精品视频| 老熟女久久久| 精品人妻一区二区三区麻豆| 老师上课跳d突然被开到最大视频| 国产高清三级在线| h视频一区二区三区| 亚洲,欧美,日韩| 精品少妇黑人巨大在线播放| 少妇高潮的动态图| 国产精品一区二区在线观看99| 免费av不卡在线播放| 国产精品久久久久久久电影| 国产免费一级a男人的天堂| 日韩av在线免费看完整版不卡| 日韩一本色道免费dvd| 只有这里有精品99| 我的女老师完整版在线观看| 日韩三级伦理在线观看| 又粗又硬又长又爽又黄的视频| 免费av中文字幕在线| 日本av手机在线免费观看| 综合色丁香网| 91精品国产国语对白视频| 国内精品宾馆在线| 熟女人妻精品中文字幕| 成年免费大片在线观看| 18禁动态无遮挡网站| 国产亚洲av片在线观看秒播厂| 联通29元200g的流量卡| 免费看不卡的av| 久久精品国产亚洲av涩爱| 欧美激情极品国产一区二区三区 | 在线观看一区二区三区激情| 国产欧美日韩精品一区二区| 99国产精品免费福利视频| 老司机影院毛片| 国产av码专区亚洲av| 欧美精品人与动牲交sv欧美| 国产一区二区三区av在线| 日韩制服骚丝袜av| 国产精品三级大全| 久久人人爽av亚洲精品天堂 | 超碰av人人做人人爽久久| 亚洲欧洲日产国产| 天堂8中文在线网| 丝袜脚勾引网站| 超碰97精品在线观看| 午夜精品国产一区二区电影| 精品视频人人做人人爽| 亚洲欧美成人精品一区二区| 大香蕉久久网| 免费观看av网站的网址| 久久热精品热| 欧美日韩视频精品一区| 亚洲怡红院男人天堂| 久久人人爽人人爽人人片va| 丰满迷人的少妇在线观看| 大片免费播放器 马上看| 男人和女人高潮做爰伦理| 建设人人有责人人尽责人人享有的 | 欧美成人a在线观看| 在线 av 中文字幕| 少妇熟女欧美另类| 中文字幕免费在线视频6| 少妇精品久久久久久久| a级一级毛片免费在线观看| 看免费成人av毛片| 我的老师免费观看完整版| 免费观看a级毛片全部| 国产精品国产三级国产av玫瑰| 狂野欧美激情性xxxx在线观看| 大片免费播放器 马上看| 在线 av 中文字幕| 蜜桃亚洲精品一区二区三区| 黄色欧美视频在线观看| 另类亚洲欧美激情| 国产成人精品久久久久久| 黄片无遮挡物在线观看| 亚洲精品色激情综合| 成人漫画全彩无遮挡| 日本一二三区视频观看| 成年免费大片在线观看| 国产一区有黄有色的免费视频| 日韩成人伦理影院| 99视频精品全部免费 在线| 自拍偷自拍亚洲精品老妇| 最近最新中文字幕免费大全7| 偷拍熟女少妇极品色| 一区二区三区免费毛片| 简卡轻食公司| 一个人免费看片子| 波野结衣二区三区在线| 日日啪夜夜撸| 久久精品国产自在天天线| 精品一区在线观看国产| 插阴视频在线观看视频| 韩国av在线不卡| 乱码一卡2卡4卡精品| 欧美+日韩+精品| 熟女电影av网| 一区在线观看完整版| 黑人猛操日本美女一级片| av卡一久久| 熟女人妻精品中文字幕| 欧美极品一区二区三区四区| 精品一品国产午夜福利视频| 波野结衣二区三区在线| 男人舔奶头视频| 18禁裸乳无遮挡动漫免费视频| 久久青草综合色| 亚洲精品日本国产第一区| 亚洲精品456在线播放app| 国产在线男女| 大陆偷拍与自拍| 国产精品av视频在线免费观看| 国国产精品蜜臀av免费| 免费观看性生交大片5| 人妻少妇偷人精品九色| 丝瓜视频免费看黄片| 欧美日本视频| 国产成人精品久久久久久| 国产精品偷伦视频观看了| 少妇人妻久久综合中文| 午夜免费鲁丝| 男人爽女人下面视频在线观看| 免费黄网站久久成人精品| 中国美白少妇内射xxxbb| 最近中文字幕2019免费版| 日韩一本色道免费dvd| 久久精品国产自在天天线| 久久久久人妻精品一区果冻| 一本久久精品| 纯流量卡能插随身wifi吗| 久久这里有精品视频免费| 伊人久久精品亚洲午夜| 天堂中文最新版在线下载| 少妇被粗大猛烈的视频| 亚洲欧洲日产国产| 国产在视频线精品| 亚洲人成网站在线播| 亚洲精华国产精华液的使用体验| 免费观看av网站的网址| 亚洲天堂av无毛| 国产国拍精品亚洲av在线观看| 一区二区三区四区激情视频| 丝袜脚勾引网站| 国产亚洲av片在线观看秒播厂| 亚洲成色77777| 成人黄色视频免费在线看| 在线观看国产h片| 日韩 亚洲 欧美在线| 免费少妇av软件| 欧美三级亚洲精品| 99久久精品热视频| 免费观看无遮挡的男女| 久久女婷五月综合色啪小说| 欧美精品一区二区免费开放| 男女国产视频网站| 亚洲婷婷狠狠爱综合网| 国产v大片淫在线免费观看| 人人妻人人爽人人添夜夜欢视频 | 久久精品国产亚洲网站| 欧美一级a爱片免费观看看| 国产av码专区亚洲av| 亚洲欧洲国产日韩| av在线播放精品| 国产精品伦人一区二区| 国产av一区二区精品久久 | 在线观看免费日韩欧美大片 | 日本黄色片子视频| 联通29元200g的流量卡| 黑丝袜美女国产一区| 99热国产这里只有精品6| 一级毛片久久久久久久久女| 久久人人爽人人片av| 秋霞伦理黄片| 肉色欧美久久久久久久蜜桃| 日韩制服骚丝袜av| 久久6这里有精品| 久久久久久人妻| 成人免费观看视频高清| 观看av在线不卡| 美女xxoo啪啪120秒动态图| 精品人妻熟女av久视频| 少妇精品久久久久久久| 女性生殖器流出的白浆| 久久国产乱子免费精品| 久久ye,这里只有精品| 一本一本综合久久| 大又大粗又爽又黄少妇毛片口| 我的老师免费观看完整版| 18禁裸乳无遮挡动漫免费视频| 91精品国产国语对白视频| 在线亚洲精品国产二区图片欧美 | 久久精品国产自在天天线| 久久综合国产亚洲精品| 99热这里只有是精品在线观看| 亚洲国产精品999| 久久99精品国语久久久| 亚洲国产欧美人成| 国产淫片久久久久久久久| 亚洲三级黄色毛片| 亚洲精品aⅴ在线观看| 免费久久久久久久精品成人欧美视频 | 国产一区有黄有色的免费视频| 伊人久久精品亚洲午夜| av在线观看视频网站免费| 夫妻午夜视频| 欧美xxxx性猛交bbbb| 亚洲无线观看免费| 91aial.com中文字幕在线观看| 日韩成人av中文字幕在线观看| 欧美日韩亚洲高清精品| 国产精品一区二区三区四区免费观看| 国产精品av视频在线免费观看| 国产免费一区二区三区四区乱码| 免费黄频网站在线观看国产| 国产探花极品一区二区| 欧美bdsm另类| 99久久综合免费| 亚洲国产毛片av蜜桃av| 亚洲av日韩在线播放| 丰满人妻一区二区三区视频av| 日本欧美国产在线视频| 美女中出高潮动态图| 男人舔奶头视频| 免费大片18禁| 91精品国产九色| 久久久久久久久久人人人人人人| 亚洲美女视频黄频| 毛片女人毛片| 国产伦精品一区二区三区四那| 男人舔奶头视频| 校园人妻丝袜中文字幕| 99热这里只有精品一区| 波野结衣二区三区在线| 十分钟在线观看高清视频www | 男人舔奶头视频| 五月玫瑰六月丁香| 毛片一级片免费看久久久久| 丝袜喷水一区| 纵有疾风起免费观看全集完整版| 久久久精品94久久精品| 卡戴珊不雅视频在线播放| 亚洲精品第二区| 一级av片app| 免费黄网站久久成人精品| 国产精品久久久久久久久免| 国产人妻一区二区三区在| 亚洲四区av| 久久国内精品自在自线图片| 亚洲国产色片| 成人综合一区亚洲| av网站免费在线观看视频| 高清av免费在线| 99热6这里只有精品| 日韩,欧美,国产一区二区三区| 成人黄色视频免费在线看| 嫩草影院入口| 亚洲第一av免费看| 免费高清在线观看视频在线观看| av国产精品久久久久影院| videos熟女内射| 午夜福利高清视频| 午夜免费鲁丝| 亚洲美女搞黄在线观看| 天堂中文最新版在线下载| 激情五月婷婷亚洲| 香蕉精品网在线| 大陆偷拍与自拍| 国产一区亚洲一区在线观看| 秋霞在线观看毛片| 久久精品夜色国产| 精品亚洲成国产av| 亚洲精品乱码久久久久久按摩| 国产高清有码在线观看视频| 亚洲精品一区蜜桃| 成人毛片a级毛片在线播放| 搡老乐熟女国产| 亚洲av不卡在线观看| 日本-黄色视频高清免费观看| 激情五月婷婷亚洲| 欧美日韩亚洲高清精品| 精品国产露脸久久av麻豆| 国产男人的电影天堂91| 亚洲欧美一区二区三区国产| 精品少妇黑人巨大在线播放| 少妇人妻久久综合中文| 国产成人aa在线观看| 亚洲最大成人中文| 丰满人妻一区二区三区视频av| 亚洲人与动物交配视频| 国产欧美亚洲国产| 日日撸夜夜添| 亚洲成人一二三区av| 在线天堂最新版资源| 视频中文字幕在线观看| 国产成人精品一,二区| 国产精品国产三级专区第一集| av卡一久久| 久久这里有精品视频免费| 男女下面进入的视频免费午夜| 一级黄片播放器| 午夜视频国产福利| 3wmmmm亚洲av在线观看| av女优亚洲男人天堂| 欧美激情极品国产一区二区三区 | 男女下面进入的视频免费午夜| 成年人午夜在线观看视频| 伦精品一区二区三区| 黑人高潮一二区| 久热久热在线精品观看| 91久久精品电影网| 亚洲高清免费不卡视频| 日韩成人伦理影院| 国产一区亚洲一区在线观看| 免费看av在线观看网站| 高清黄色对白视频在线免费看 | 久久影院123| 国产日韩欧美在线精品| 3wmmmm亚洲av在线观看| 亚洲欧美一区二区三区国产| 国产av精品麻豆| 黄色怎么调成土黄色| 国产淫语在线视频| 久久久成人免费电影| 天堂俺去俺来也www色官网| 91午夜精品亚洲一区二区三区| 精品少妇久久久久久888优播| 男女无遮挡免费网站观看| 久久精品久久久久久噜噜老黄| 久久人人爽人人片av| 免费观看在线日韩| 国产成人a∨麻豆精品| 亚洲人成网站在线观看播放| 99热网站在线观看| 中文字幕制服av| 自拍偷自拍亚洲精品老妇| 久久久久网色| h日本视频在线播放| 一级毛片久久久久久久久女| av专区在线播放| av免费在线看不卡| 内地一区二区视频在线| 日日啪夜夜撸| 国产精品一区www在线观看| 高清午夜精品一区二区三区| 久久97久久精品| 中文资源天堂在线| 国产亚洲午夜精品一区二区久久| 在线观看人妻少妇| 一区二区av电影网| 久热久热在线精品观看| 亚洲av国产av综合av卡| 五月天丁香电影| 插逼视频在线观看| 天天躁日日操中文字幕| 99国产精品免费福利视频| 激情五月婷婷亚洲| 美女中出高潮动态图| 色吧在线观看| 久久久久久人妻| 亚洲精品日韩av片在线观看| 青春草国产在线视频| 午夜福利高清视频| av不卡在线播放| 99视频精品全部免费 在线| 国产成人免费无遮挡视频| 精品少妇黑人巨大在线播放| 激情五月婷婷亚洲| 亚洲丝袜综合中文字幕| 中文精品一卡2卡3卡4更新| 最近最新中文字幕大全电影3| 亚洲国产av新网站| 久久久久久久国产电影| 观看av在线不卡| 免费看av在线观看网站| 国产乱人视频| 热99国产精品久久久久久7| av天堂中文字幕网| 久久97久久精品| 亚洲久久久国产精品| 国产亚洲91精品色在线| av在线app专区| 亚洲国产av新网站| 久久久久久久大尺度免费视频| 亚洲精品,欧美精品| 99久国产av精品国产电影| 亚洲成人av在线免费| 啦啦啦视频在线资源免费观看| 亚洲性久久影院| 亚洲精品国产色婷婷电影| 免费人成在线观看视频色| 日韩中文字幕视频在线看片 | 成人黄色视频免费在线看| 99热6这里只有精品| 亚洲av欧美aⅴ国产| 国产精品嫩草影院av在线观看| 国产精品久久久久久久电影| 欧美成人a在线观看| 欧美激情极品国产一区二区三区 | 亚洲av男天堂| 欧美高清性xxxxhd video| 免费观看a级毛片全部| 久久久久性生活片| 久久精品人妻少妇| 久久精品夜色国产| 22中文网久久字幕| 国产 精品1| 日韩欧美 国产精品| 男人爽女人下面视频在线观看| 亚洲第一区二区三区不卡| 插阴视频在线观看视频| 色网站视频免费| 一级毛片我不卡| 国产av码专区亚洲av| 最后的刺客免费高清国语| 国产高清不卡午夜福利| 国模一区二区三区四区视频| 亚洲成色77777| 丰满少妇做爰视频| 最近中文字幕2019免费版| 97在线视频观看| 精品一品国产午夜福利视频| 亚洲内射少妇av| 成年女人在线观看亚洲视频| 亚洲国产欧美人成| 欧美+日韩+精品| videossex国产| 寂寞人妻少妇视频99o| 99热6这里只有精品| 少妇被粗大猛烈的视频| 免费黄频网站在线观看国产| 亚洲精品国产成人久久av| 秋霞伦理黄片| 国产男人的电影天堂91| 夜夜爽夜夜爽视频| 亚洲国产欧美在线一区| 男女无遮挡免费网站观看| 欧美另类一区| 欧美高清成人免费视频www| 美女xxoo啪啪120秒动态图| 国产伦在线观看视频一区| 日本av手机在线免费观看| 看十八女毛片水多多多| 欧美日韩国产mv在线观看视频 | 久久影院123| 99国产精品免费福利视频|